Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · IEX Real-Time Price · USD
37.65
-0.27 (-0.71%)
At close: Mar 28, 2024, 4:00 PM
37.14
-0.51 (-1.35%)
After-hours: Mar 28, 2024, 5:40 PM EDT

Janux Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019
Market Capitalization
1,959495549821--
Market Cap Growth
--9.72%-33.17%---
Enterprise Value
1,639175246445-83
PE Ratio
-8.50-8.50-8.70-25.13--
PS Ratio
242.3561.2963.71225.73--
PB Ratio
5.691.441.712.24--
P/FCF Ratio
-9.45-9.45-11.11-44.48--
P/OCF Ratio
-9.80-9.80-12.78-48.36--
EV/Sales Ratio
202.7321.6628.59122.47--
EV/EBITDA Ratio
-3.11-3.11-3.96-13.681.19-0.89
EV/EBIT Ratio
-3.00-3.00-3.90-13.631.19-0.89
EV/FCF Ratio
-3.34-3.34-4.99-24.131.79-0.87
Debt / Equity Ratio
0.070.070.080.00--0.50
Debt / EBITDA Ratio
-0.44-0.44-0.41-0.01--1.06
Debt / FCF Ratio
-0.47-0.47-0.51-0.01--1.04
Quick Ratio
26.4626.4619.8629.364.970.14
Current Ratio
26.8026.8020.1429.465.050.14
Asset Turnover
0.020.020.020.010-
Interest Coverage
-----31.93-16.18
Return on Equity (ROE)
-17.90%-17.90%-18.70%-11.80%60.10%-
Return on Assets (ROA)
-16.00%-16.00%-16.90%-10.50%-80.30%-
Return on Capital (ROIC)
-19.78%-19.78%-19.39%-8.98%33.09%95.61%
Earnings Yield
-2.98%-11.77%-11.49%-3.98%--
FCF Yield
-2.68%-10.58%-9.00%-2.25%--
Buyback Yield / Dilution
-6.14%-6.14%-76.24%-2471.20%-36.71%-
Total Shareholder Return
-6.14%-6.14%-76.24%-2471.20%-36.71%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).